Abstract
Oral polio vaccine (OPV) proved to be superior in administration eliminating the need of sterile syringes and making the vaccine more suitable for mass vaccination campaigns. Poliovirus is heat sensitive in nature, and thus OPV is stored at low temperature (frozen). The growth medium containing varying concentration of serum such as 6, 8, 10, 12, 14% were prepared. 10 ml of the above mentioned growth media containing different concentration of serum were added to different culture bottles. The culture flasks containing different volumes of growth medium with 10% serum concentration such as 8, 9, 10, 11 and 12 ml were added to a series of culture flasks. All the culture flasks were inoculated with the RD cells (10,000 cells/culture flask) and kept at 37°C. The most favoured serum concentration and volume for the growth of RD cells was found and used for testing the potency of vaccine. Vaccines from two manufacturers were kept at three different temperatures, 2-8 ± 0.5°C (refrigerator), 26 ± 0.5°C and 37 ± 0.5°C (Incubator). Cytopathic viruses were titrated by the determination of a tissue culture infectious dose50 (TCID50), vaccine dilutions were seeded in replicate onto cells in multiwell plates (usually 96 wells). After a suitable incubation period, wells were examined microscopically and scored as infected or not infected. The potency of vaccines was tested using the Karber’s Formula. Key words: Oral polio vaccine, rhabdomyosarcoma, thermostability, potency.
Highlights
Poliomyelitis, often called polio or infantile paralysis, is an acute viral infectious disease spread from person to person, primarily via the faecal-oral route
The culture flasks containing different volumes of growth medium with 10% serum concentration such as 8, 9, 10, 11 and 12 ml were added to a series of culture flasks
Different volumes of the media were studied with respect to their effect on RD cell growth after observing for three days
Summary
Poliomyelitis, often called polio or infantile paralysis, is an acute viral infectious disease spread from person to person, primarily via the faecal-oral route. Effective poliovirus vaccines have been available for over a quarter of a century, paralytic poliomyelitis remains a serious health risk in many countries. In developing countries the incidence of the disease remains high. Even though concerted vaccination campaigns have improved the situation in certain regions, more urgent health priorities or difficulties arising from poor economies or political uncertainty, have meant that vaccination against poliomyelitis worldwide has not been sufficiently comprehensive to have had a major impact on the total global incidence of the disease. Poliomyelitis, greatly diminished in incidence, has not disappeared. Developed countries generally experienced a dramatic decrease in poliomyelitis after vaccination was introduced, those countries using the live-attenuated vaccines developed by Albert Bruce Sabin have noted a residual low level of approximately 0.02 - 0.2 cases/million of population/ years. Evidence has accumulated that this persistent low level of disease may be caused by the vaccines themselves, especially those of serotypes 2 and 3
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
